

Name of journal: World Journal of Gastroenterology

Manuscript NO: 39372

Manuscript type: Minireview

Vedolizumab for inflammatory bowel disease: from randomized controlled trials to real-life evidence

05 May 2018

Dear Editor,

I thank you for your evaluation of my manuscript and the reviewers for their suggestions.

I have considered the Editorial comments and the reviewers suggestions and I have revised the manuscript accordingly. All the revisions have been highlighted in the updated version of the manuscript.

***Reviewer's 00035901 comments to the Authors***

*The authors timely reviewed the efficacy, safety, and tolerability of vedolizumab reported in both randomized, controlled, clinical trials and from real-world experience in patients with UC and CD in order to identify its place in treatment algorithms for IBD. This review will give us an important information, especially in the field of clinical gastroenterology. We have no claim in the present paper.*

**Answer:** I thank the reviewer for his very positive feedback on my manuscript.

***Reviewer's 00159305 comments to the Authors***

*To the Author, Good piece of work, well written. I have no concerns about your manuscript.*

**Answer:** I thank the reviewer for his very positive feedback on my manuscript.

***Reviewer's 000570280 comments to the Authors***

*This is an interesting review. Few suggestions to the authors, they can include a diagram to explain the action of the drug. Secondly they should discuss data on combination of vedolizumab with anti TNF. Finally if*

*available data on Asian patients can be included as well as Asian IBD is different both genetically and phenotypically. Minor corrections. page 4 generalisation is spelt wrong.*

**Answer:** I thank the reviewer for his constructive suggestions.

I have included a figure to explain the action of the drug. I have included some data on combination of vedolizumab with anti TNF therapy. I agree with the reviewer that data on Asian IBD patients can be interesting. Some clinical trials to evaluate the efficacy and the safety of vedolizumab in Asian patients with IBD are ongoing or have been completed very recently. However, the results have still not been published in full. The word generalisation has been corrected.

Thank you very much for your attention.

Yours faithfully,

Maria Lia Scribano

Maria Lia Scribano, MD

IBD Unit

Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy

e-mail address: [marialiascribano@virgilio.it](mailto:marialiascribano@virgilio.it)